Psychiatry Research
Volume 133, Issue 2 , Pages 253-261 , 28 February 2005

Doxapram-induced panic attacks and cortisol elevation

  • David A. Gutman

      Affiliations

    • Department of Psychiatry, Columbia University School of Medicine, 1051 Riverside Drive, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 342 1101; fax: +1 419 730 3208.
    • ,
  • Jeremy Coplan

      Affiliations

    • Department of Psychiatry, State University of New York, Downstate, Brooklyn, NY, USA
    • ,
  • Laszlo Papp

      Affiliations

    • New York State Psychiatric Institute, New York, NY, USA
    • ,
  • Jose Martinez

      Affiliations

    • Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    • ,
  • Jack Gorman

      Affiliations

    • Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    • Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA

Received 29 August 2004 ,Accepted 26 October 2004.

References 

  1. Abelson JL, Curtis GC, Nesse R, Fantone R, Pyke RE, Bammert-Adams J. The effects of central cholecystokinin receptor blockade on hypothalamic–pituitary–adrenal and symptomatic responses to overnight withdrawal from alprazolam. Biological Psychiatry. 1995;37:56–59
  2. Abelson JL, Nesse RM, Weg JG, Curtis GC. Respiratory psychophysiology and anxiety: cognitive intervention in the doxapram model of panic. Psychosomatic Medicine. 1996;58:302–313
  3. Abelson JL, Weg JG, Nesse RM, Curtis GC. Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model. Psychoneuroendocrinology. 1996;21:375–390
  4. American Psychiatric Association . The Diagnostic and Statistical Manual of Mental Disorders (DSM-III R). Washington, DC: Author; 1987;
  5. Austin DW, Richards JC. The catastrophic misinterpretation model of panic disorder. Behaviour Research and Therapy. 2001;39:1277–1291
  6. Borg GA. Psychophysical bases of perceived exertion. Medicine and Science in Sports and Exercise. 1982;14:377–381
  7. Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Annals of the New York Academy of Sciences. 1994;713:273–282
  8. Bradwejn J, Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scandinavian Journal of Clinical & Laboratory Investigation Supplement. 2001;234:19–27
  9. Burki NK. Ventilatory effects of doxapram in conscious human subjects. Chest. 1984;85:600–604
  10. Calverley PM, Robson RH, Wraith PK, Prescott LF, Flenley DC. The ventilatory effects of doxapram in normal man. Clinical Science. 1983;65:65–69
  11. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry. 1984;41:751–763
  12. Coplan J, Klein D. Pharmacological probes in panic disorder. In:  Westenberg H,  Boer J,  Murphy D editor. Advances in the Neurobiology of Anxiety Disorders. Chichester: Wiley; 1996;p. 173–196
  13. Coplan JD, Pine D, Papp L, Martinez J, Cooper T, Rosenblum LA, et al. Uncoupling of the noradrenergic–hypothalamic–pituitary–adrenal axis in panic disorder patients. Neuropsychopharmacology. 1995;13:65–73
  14. Coplan JD, Papp LA, Pine D, Martinez J, Cooper T, Rosenblum LA, et al. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Archives of General Psychiatry. 1997;54:643–648
  15. Coplan JD, Trost RC, Owens MJ, Cooper TB, Gorman JM, Nemeroff CB, et al. Cerebrospinal fluid concentrations of somatostatin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions. Archives of General Psychiatry. 1998;55:473–477
  16. Coplan JD, Goetz R, Klein DF, Papp LA, Fyer AJ, Liebowitz MR, et al. Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. Archives of General Psychiatry. 1998;55:130–136
  17. Davis M. The role of the amygdala in fear and anxiety. Annual Review of Neuroscience. 1992;15:353–375
  18. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF. Measurement of lactate-induced panic and anxiety. Psychiatry Research. 1987;20:97–105
  19. Folgering H, Vis A, Ponte J. Ventilatory and circulatory effects of doxapram, mediated by carotid body chemoreceptors. Bulletin Europeen de Physiopathologie Respiratoire. 1981;17:237–241
  20. Gorman JM, Fyer MR, Goetz R, Askanazi J, Liebowitz MR, Fyer AJ, et al. Ventilatory physiology of patients with panic disorder. Archives of General Psychiatry. 1988;45:31–39
  21. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry. 2000;157:493–505
  22. Jensen CF, Peskind ER, Veith RC, Hughes J, Cowley DS, Roy-Byrne P, et al. Hypertonic saline infusion induces panic in patients with panic disorder. Biological Psychiatry. 1991;30:628–630
  23. Kent, J.M., Coplan J.D., Mawlawi O., Martinez J.M., Browne S.T., Slifstein M., Martinez D., Abi-Dargham A., Laruelle M., Gorman J.M., in press. Reduced orbitofrontal CBF predicts panic response to a respiratory stimulant in panic disorder. American Journal of Psychiatry.
  24. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biological Psychiatry. 1991;30:973–984
  25. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depression and Anxiety. 1998;8:1–7
  26. LeDoux J. The Emotional Brain: The Mysterious Underpinnings of Emotional Life. New York: Simon and Schuster; 1996;
  27. LeDoux JE, Iwata J, Cicchetti P, Reis DJ. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. Journal of Neuroscience. 1988;8:2517–2529
  28. Lee YJ, Curtis GC, Weg JG, Abelson JL, Modell JG, Campbell KM. Panic attacks induced by doxapram. Biological Psychiatry. 1993;33:295–297
  29. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, et al. Lactate provocation of panic attacks: II. Biochemical and physiological findings. Archives of General Psychiatry. 1985;42:709–719
  30. Mathew SJ, Coplan JD, Perko KA, Goetz RR, de la Neuz M, Hollander E, et al. Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive–compulsive disorder. Depression and Anxiety. 2001;14:199–208
  31. Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz MR, et al. Diagnostic and substance specificity of carbon-dioxide-induced panic. American Journal of Psychiatry. 1993;150:250–257
  32. Pyke RE, Greenberg HS. Norepinephrine challenges in panic patients. Journal of Clinical Psychopharmacology. 1986;6:279–285
  33. Spitzer R, Williams J, Gibbon M, First M. Structured Clinical Interview for the DSM III-R. American Psychiatric Association; 1990;
  34. Sullivan GM, Apergis J, Gorman JM, LeDoux JE. Rodent doxapram model of panic: behavioral effects and c-fos immunoreactivity in the amygdala. Biological Psychiatry. 2003;53:863–870
  35. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Research. 1989;28:295–306
  36. Veltman DJ, van Zijderveld GA, van Dyck R. Epinephrine infusions in panic disorder: a double-blind placebo-controlled study. Journal of Affective Disorders. 1996;39:133–140
  37. Winnie AP. Chemical respirogenesis: a comparative study. Acta Anaesthesiologica Scandinavica. Supplement. 1973;51:1–32

PII: S0165-1781(04)00271-9

doi: 10.1016/j.psychres.2004.10.010

Psychiatry Research
Volume 133, Issue 2 , Pages 253-261 , 28 February 2005

Article Tools

* Image Usage & Resolution